SRR820623
GTEX
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- GTEX
- cancer_type_detailed
- —
- subtype
- —
- cancer_type
- GTEX
- sex
- Male
GSVA pathway preview (0 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR663753 | GTEX | — | 0.979 |
| 2 | SRR1471943 | GTEX | — | 0.969 |
| 3 | SRR1323106 | GTEX | — | 0.966 |
| 4 | SRR1455925 | GTEX | — | 0.965 |
| 5 | SRR1084842 | GTEX | — | 0.963 |
| 6 | SRR818210 | GTEX | — | 0.963 |
| 7 | SRR658129 | GTEX | — | 0.957 |
| 8 | SRR613090 | GTEX | — | 0.954 |
| 9 | SRR1349056 | GTEX | — | 0.950 |
| 10 | SRR821626 | GTEX | — | 0.950 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 8 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| SPERMATOGENESIS | 0.297 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.209 | Remibrutinib | — uncovered |
| KRAS_SIGNALING_DN | 0.161 | Remibrutinib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.156 | Remibrutinib | — uncovered |
| PANCREAS_BETA_CELLS | 0.133 | Cobimetinib | — uncovered |
| HEDGEHOG_SIGNALING | 0.044 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.031 | Inavolisib | — uncovered |
| HEME_METABOLISM | 0.006 | Temsirolimus | — uncovered |